These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35539318)

  • 1. Nanodiamond-based layer-by-layer nanohybrids mediate targeted delivery of miR-34a for triple negative breast cancer therapy.
    Xia Y; Deng X; Cao M; Liu S; Zhang X; Xiao X; Shen S; Hu Q; Sheng W
    RSC Adv; 2018 Apr; 8(25):13789-13797. PubMed ID: 35539318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion.
    Bayraktar R; Ivan C; Bayraktar E; Kanlikilicer P; Kabil NN; Kahraman N; Mokhlis HA; Karakas D; Rodriguez-Aguayo C; Arslan A; Sheng J; Wong S; Lopez-Berestein G; Calin GA; Ozpolat B
    Clin Cancer Res; 2018 Sep; 24(17):4225-4241. PubMed ID: 29748184
    [No Abstract]   [Full Text] [Related]  

  • 3. Layer-by-layer assembled PLGA nanoparticles carrying miR-34a cargo inhibit the proliferation and cell cycle progression of triple-negative breast cancer cells.
    Kapadia CH; Ioele SA; Day ES
    J Biomed Mater Res A; 2020 Mar; 108(3):601-613. PubMed ID: 31742868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual Regulation of miR-34a and Notch Signaling in Triple-Negative Breast Cancer by Antibody/miRNA Nanocarriers.
    Valcourt DM; Day ES
    Mol Ther Nucleic Acids; 2020 Sep; 21():290-298. PubMed ID: 32622330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PDL1 And LDHA act as ceRNAs in triple negative breast cancer by regulating miR-34a.
    Huang X; Xie X; Wang H; Xiao X; Yang L; Tian Z; Guo X; Zhang L; Tang H; Xie X
    J Exp Clin Cancer Res; 2017 Sep; 36(1):129. PubMed ID: 28915924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer.
    Adams BD; Wali VB; Cheng CJ; Inukai S; Booth CJ; Agarwal S; Rimm DL; Győrffy B; Santarpia L; Pusztai L; Saltzman WM; Slack FJ
    Cancer Res; 2016 Feb; 76(4):927-39. PubMed ID: 26676753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Degradable hyaluronic acid/protamine sulfate interpolyelectrolyte complexes as miRNA-delivery nanocapsules for triple-negative breast cancer therapy.
    Wang S; Cao M; Deng X; Xiao X; Yin Z; Hu Q; Zhou Z; Zhang F; Zhang R; Wu Y; Sheng W; Zeng Y
    Adv Healthc Mater; 2015 Jan; 4(2):281-90. PubMed ID: 25044638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. circGFRA1 and GFRA1 act as ceRNAs in triple negative breast cancer by regulating miR-34a.
    He R; Liu P; Xie X; Zhou Y; Liao Q; Xiong W; Li X; Li G; Zeng Z; Tang H
    J Exp Clin Cancer Res; 2017 Oct; 36(1):145. PubMed ID: 29037220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Layer-by-layer assembled gold nanoshells for the intracellular delivery of miR-34a.
    Goyal R; Kapadia CH; Melamed JR; Riley RS; Day ES
    Cell Mol Bioeng; 2018 Oct; 11(5):383-396. PubMed ID: 30555597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
    Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer.
    Weng YS; Tseng HY; Chen YA; Shen PC; Al Haq AT; Chen LM; Tung YC; Hsu HL
    Mol Cancer; 2019 Mar; 18(1):42. PubMed ID: 30885232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-34a-Mediated Survivin Inhibition Improves the Antitumor Activity of Selinexor in Triple-Negative Breast Cancer.
    Martini S; Zuco V; Tortoreto M; Percio S; Campi E; El Bezawy R; Doldi V; Landesman Y; Pennati M; Zaffaroni N
    Pharmaceuticals (Basel); 2021 May; 14(6):. PubMed ID: 34072442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor suppressor role of microRNA-1296 in triple-negative breast cancer.
    Phan B; Majid S; Ursu S; de Semir D; Nosrati M; Bezrookove V; Kashani-Sabet M; Dar AA
    Oncotarget; 2016 Apr; 7(15):19519-30. PubMed ID: 26799586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymer-Initiating Caveolae-Mediated Endocytosis and GSH-Responsive MiR-34a Gene Delivery System for Enhanced Orthotopic Triple Negative Breast Cancer Therapy.
    Han TY; Huan ML; Cai Z; He W; Zhou SY; Zhang BL
    Adv Healthc Mater; 2023 Dec; 12(32):e2302094. PubMed ID: 37827986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The long noncoding RNA sONE represses triple-negative breast cancer aggressiveness through inducing the expression of miR-34a, miR-15a, miR-16, and let-7a.
    Youness RA; Hafez HM; Khallaf E; Assal RA; Abdel Motaal A; Gad MZ
    J Cell Physiol; 2019 Nov; 234(11):20286-20297. PubMed ID: 30968427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1.
    Chen LL; Zhang ZJ; Yi ZB; Li JJ
    Br J Cancer; 2017 Jun; 117(1):78-88. PubMed ID: 28571042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
    Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
    Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of miRNA-3613-3p Enhances the Sensitivity of Triple Negative Breast Cancer to CDK4/6 Inhibitor Palbociclib.
    Yu Y; Liao H; Xie R; Zhang Y; Zheng R; Chen J; Zhang B
    Front Oncol; 2020; 10():590813. PubMed ID: 33330073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-506-loaded gelatin nanospheres target PENK and inactivate the ERK/Fos signaling pathway to suppress triple-negative breast cancer aggressiveness.
    Liu XL; Liu WJ; Chen Q; Liu J; Yang CQ; Zhang G; Zhang SL; Guo WH; Li JB; Zhao G; Yin DC; Zhang CY
    Mol Carcinog; 2021 Aug; 60(8):538-555. PubMed ID: 34062009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exosomes-Coated miR-34a Displays Potent Antitumor Activity in Pancreatic Cancer Both in vitro and in vivo.
    Zuo L; Tao H; Xu H; Li C; Qiao G; Guo M; Cao S; Liu M; Lin X
    Drug Des Devel Ther; 2020; 14():3495-3507. PubMed ID: 32921986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.